Results of the NOVA study show that Myriad Genetics Inc.’s myChoice HRD can identify the ovarian cancer of patients who are most likely to benefit from Tesaro Inc.’s investigational drug niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP-inhibitor). But it remains to be seen if testing with the companion diagnostic will be included in niraparib’s approved indication or not.
Myriad is pursuing US FDA approval for myChoice HRD as a companion diagnostic designation with niraparib in this patient population of highly platinum-sensitive patients undergoing maintenance therapy.